VIDEO: ‘Explosion’ of incretin therapy use among new developments in cardiology
NEW ORLEANS — In this video, Clyde W. Yancy, MD, MSc, MACP, MACC, FAHA, FHFSA, discusses notable updates across several areas of cardiology he presented at the ACP Internal Medicine Meeting.
Yancy, a professor and chief of cardiology at Northwestern University Feinberg School of Medicine, highlighted advancements in the treatment of heart failure during a time where deaths caused by the disease have recently reached significant highs in the U.S.
“We’re able to finally talk about truly evidence-based therapies that allow us to change the natural history for heart failure with preserved ejection fraction,” he explained. “We’re able to review about 50 years of information that emphatically demonstrate the progress we’ve made in reducing the risk of death and disability due to heart failure by at least 50% over the last several decades.”
Yancy also talked about improved knowledge about risk modification for conditions like hypertension and the “continued explosion of the use of the incretin therapies in the cardiovascular space.”
“We’re completely engaged, yet we understand we have to navigate the cost of therapy and the equation that is the difference between cost and value,” he added.